Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024
March 11, 2020 01:01 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the...
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 09, 2020 16:02 ET
|
Assertio Therapeutics, Inc.
-- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5...
Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020
March 02, 2020 17:30 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019...
Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt
February 19, 2020 08:00 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated...
Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
February 13, 2020 16:05 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed definitive...
Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
February 06, 2020 16:01 ET
|
Assertio Therapeutics, Inc.
Company Intends to Use Cash Proceeds to Retire its Outstanding Debt Company Intends to Use Improved Balance Sheet to Pursue Business Development, Strategic Partnerships and Investment...
Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance
January 13, 2020 07:50 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreement...
Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million
December 12, 2019 07:50 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (NASDAQ: ASRT), today announced it has entered into an agreement with Alvogen, a global privately held...
Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 26, 2019 14:28 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 31st Annual Piper Jaffray...
Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference
November 13, 2019 12:58 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Stifel Healthcare Conference...